















revascularization through an eNOS dependent
pathway in the ischemic hindlimb mice model
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Objective: As ﬁrst-line treatment for type 2 diabetes, metformin has gained a strong position. In addition, type 2 diabetics
beneﬁt from the fact that metformin is associated with a reduction in cardiovascular events. Nevertheless, there is a dearth
of information concerning the functional role of metformin in regulating angiogenesis. Our present study explores
whether metformin is involved in the modulation of the revascularization processes in vivo by employing a hindlimb mice
model of ischemia-induced angiogenesis.
Methods: For comparative purposes, randomly selected wild-type (WT) mice or endothelial nitric oxide synthase (eNOS)
deﬁcient mice were assigned to one of two groups. One group was orally administered a daily dose of metformin through
a gastric tube whereas the other group served as a control with no metformin administered. Both groups were subjected to
unilateral hindlimb ischemia. Laser Doppler analysis coupled with capillary density staining with CD31was the method
employed to determine revascularization. Adenosine monophosphate-activated protein kinase (AMPK) and eNOS
phosphorylation levels were assessed using Western blot analysis.
Results: Subsequent to hindlimb ischemic surgery, in comparison to the nontreated mice, metformin-treated WT mice
showed accelerated limb perfusion, which was substantiated by laser Doppler blood-ﬂow measurements and the presence
of increased capillary density in the ischemic adductor muscle. Treatment with metformin signiﬁcantly enhanced the
increase in AMPK and eNOS phosphorylation levels of muscle tissues in WT mice induced by ischemia. In eNOS-
deﬁcient knockout mice, there was a signiﬁcant increase in ischemic tissue AMPK phosphorylation induced by metformin;
however, blood ﬂow recovery in ischemic limb after surgery was unaffected.
Conclusions: Metformin promoted revascularization in the presence of tissue ischemia through an AMPK/eNOS-related
mechanism. Our study indicates that, in addition to its glucose-lowering effect, metformin fosters improved revas-
cularization, which is responsible for its positive effect on patients with critical limb ischemia. (J Vasc Surg
2015;61:489-96.)
Clinical Relevance: In patients with peripheral arterial disease, the incidence of the diabetes mellitus is high. One of the
comorbidities that affect wound healing is diabetes. In Japan, in particular, the complication rates of diabetes mellitus and
end-stage renal disease are high in patients with critical limb ischemia. Metformin is a widely used ﬁrst-line drug for the
treatment of type2 diabetes. The present study indicates that, in addition to its glucose-lowering effect, metformin has
beneﬁcial effects on the improvement of revascularization, which produce positive effects on the patient with critical limb
ischemia.As ﬁrst-line treatment for type2 diabetes, metformin
(N’,N’- dimethylbiguanide) has gained a strong position.
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://dx.doi.org/10.1016/j.jvs.2013.09.061metformin lessened the risk of macrovascular-related
complications and all-cause mortality to a greater extent
than is obtained through conventional therapies associated
with similar levels of lowered blood glucose.1 Metformin
has also displayed a correlation with decreased all-cause
and cardiovascular risk of mortality.2-4 Recently, it has
been reported that monotherapy involving the most
common insulin secretagogues appears to be linked with
increased mortality as well as greater cardiovascular risk in
comparison to treatment with metformin.5,6 Furthermore,
several authors have indicated the existence of a symptom-
atic beneﬁt from metformin treatment in peripheral artery
disease patients.7,8 Thus, clinical studies have led to the
concept that metformin produces cardiovascular protective
effects that are partly independent form its glycemic control
function.
These clinical observations are in agreement with
several experimental studies that have suggested that489
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affects vascular endothelial function and atherosclerosis.
Metformin inhibits proinﬂammatory response and apo-
ptosis in human vascular wall cells.9,10 Metformin treat-
ment is also associated with a decrease in the activity of
plasminogen activator inhibitor-1 and tissue plasminogen
antigen11,12 and improvement of capillary ﬂow.13 Further-
more, metformin treatment attenuated vascular remodel-
ing in monosodium glutamate-induced obese rats.14
Numerous experimental studies indicate that activation
of adenosine monophosphate-activated protein kinase
(AMPK) partly mediates the pleiotropic effects of metfor-
min.15-17 As a stress-activated protein kinase, AMPK plays
a role in the regulation of energy and metabolic homeo-
stasis.18-20 Metformin activates AMPK in multiple cell
types such as hepatocytes and endothelial cells.15-17 It has
also been reported that AMPK directly phosphorylates
endothelial nitric oxide synthase (eNOS).21 In addition,
it has been shown that various AMPK activators, as a result
of their ability to activate AMPK, stimulate phosphoryla-
tion of eNOS in endothelial cells and promote endothelial
function.16,22-24 However, there is a dearth of information
about the functional role of metformin, an AMPK acti-
vator, in regulating angiogenesis. In this study, we explored
whether or not metformin modulates the revascularization
processes in vivo by employing a hindlimb model of
ischemia-induced angiogenesis.METHODS
Cell Signaling Technology Inc (Beverly, Mass) was the
supplier for the following primary antibodies: phospho-
eNOS antibody, eNOS antibody, phospho-AMPK (Thr
172) antibody, AMPK antibody, and a-tubulin antibody.
Dainipponn Sumitomo Pharmaceutical Co (Tokyo, Japan)
provided metformin as a generous gift.
Animals and experimental protocol. Male wild-type
mice (WT) and e-NOS deﬁcient knockout (eNOS-KO)
mice in a C57BL/6J background between the ages of 8
and 10 weeks old served as the experimental subjects in
this study.25,26 Western blot analysis was previously used
to conﬁrm that eNOS-KO mice are deﬁcient in eNOS
protein.25The Institutional AnimalCare andUseCommittee
of Nagoya University School of Medicine approved the
study protocol. We employed a mouse model of neo-
vascularization by surgically removing the entire left
femoral artery and under anesthesia with sodium pento-
barbital (50 mg/kg intraperitoneally) as previously
described.23,27,28 Mice were randomly assigned to one of
three groups. Starting at 1 day prior to surgery and
continued for 4 weeks, one group received oral admin-
istration of metformin (150 or 300 mg/kg/d, with 0.9%
saline) by gastric tube, and the control group received
oral administration of saline (0.2 mL/d) by gastric tube.
We ﬁxed the dosages at 150 or 300 mg/kg/d, since
some groups of researchers had conﬁrmed that these
dosages were sufﬁcient to investigate the effects of met-
formin in experimental mouse models.29,30Laser Doppler blood ﬂow analysis and clinical
score. Hindlimb blood ﬂow was measured with a laser
Doppler blood ﬂowmetry (LDBF; MoorLDI, Moor
Instrument, Devon, UK), as previously described.23,27,28
Before and on postoperative day 0, 3, 7, 14, 21, and 28,
LDBF analysis on the legs and feet was performed.
Depilatory cream was used to remove excess hairs from the
limb before imaging. To minimize temperature variation,
we placed the mice on a heating plate at 37C. We
analyzed the stored scanned images to quantify blood ﬂow
and calculate the mean LDBF values of the ischemic and
nonischemic limbs. To circumvent the possible occurrence
of variations in data as a result from interference from
ambient light and temperature, we expressed hindlimb
blood ﬂow as a ratio of the left (ischemic) to right (non-
ischemic) hindlimb LDBF.
We designed a scoring system to more precisely eval-
uate the mobility of mice after limb ischemia: 0 ¼ normal;
1 ¼ pale foot or gait abnormalities; 2 ¼ less than one-half
of the foot is necrotic; 3 ¼more than one-half of the foot is
necrotic without lower leg necrosis; 4 ¼ more than one-
half of the foot is necrotic with some lower leg necrosis;
and 5 ¼ necrosis or auto amputation of entire lower
limb. To obtain blood ﬂow measurements, we carried
out observation and recoding of the clinical scores for the
mice at the same points in time.23
Capillary and arteriole density analysis. Analysis of
the capillary density within thigh adductor muscle yielded
speciﬁc evidence concerning microcirculation vascularity.
On postoperative day 28, we gathered tissue samples
from the ischemic thigh adductor skeletal muscles. From
each sample, we removed 5 um-thick tissue sections and
froze them.
Tissue capillary and arteriole density were measured by
histochemical staining with anti-mouse CD31 (BD Biosci-
ences, San Jose, Calif) and anti-mouse a-smooth muscle
actin (Sigma, St. Louis, Mo). To analyze capillary and arte-
riole density, we randomly chose 15 microscopic ﬁelds from
three different sections in each tissue block. Capillary and
arteriole density were expressed as the quantity of CD31-
positive cells and a-smooth muscle actin positive cells per
high power ﬁeld (400).23,27 A researcher blinded with
respect to the samples preformed these quantiﬁcations.
Plasma parameter measurement. Enzymatic kits
(Wako Chemicals, Osaka, Japan) were used to measure
plasma glucose and insulin levels. Blood was drawn from
the mice by heart puncture on postoperative day 28.
Western blot analysis. Postoperative-day 7 tissue
samples were homogenized in a lysis buffer prepared from
20 mm Tris-HCl (pH 8.0), 1% Nonidet P-40, 150 mM
NaCl, 0.5% deoxycholic acid, 1 mM sodium orthovana-
date, and protease inhibitor mixture (Roche, Mannheim,
Germany). Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis was employed to resolve cell lysates or
culture media. Immunoblotting of the membranes with
the indicated antibodies was carried out at a 1:1000 dilu-
tion in conjunction with subsequent secondary antibody









































Fig 1. Metformin improves perfusion of ischemic limbs in wild-type (WT) mice. A, Representative images of laser
Doppler blood ﬂowmetry (LDBF) for WT mice treated with or without metformin before surgery and at different time
points after surgery. Low perfusion signals (dark blue) were observed in the ischemic hindlimb of WT mice, whereas
high perfusion signals (white to red) were detected in WT mice treated with metformin on postoperative day 3, 7, 14,
21, and 28. B,Quantitative analysis of ischemic/normal LDBF ratio in WT mice (n ¼ 10 in each group) treated with or
without metformin (*P < .05 vs control).
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plus Western Blotting Detection kit (GE Healthcare, Little
Chalfont, Buckinghamshire, England). Quantiﬁcation of
relative phosphorylation or protein levels was done using
the Image J program. Immunoblots were normalized to a-
tubulin.
Statistical analysis. Data are presented as mean 6
standarderror asdenoted in theﬁgure legends. Statistical anal-
ysis was performed by analysis of variance followed by
Turkey’s honestly signiﬁcant difference test or Student paired
t-test.AP valueof<.05was acceptedas statistically signiﬁcant.
RESULTS
Effect of metformin on ischemia-induced revascu-
larization. We subjected WT mice, treated with or
without metformin, to unilateral hindlimb ischemia for
the assessment of metformin’s effect on the process of
revascularization in response to ischemia. All mice survived
surgery and remained healthy throughout the follow-up
period. Metformin treatment (300 mg/kg/d) had no effect
on glucose in WT mice as previously described (metformin-
treated WT mice: 100.2 6 9.8 mg/dL and untreated mice:
101.6 6 9.6 mg/dL).31 Representative LDBF images ofhindlimb blood ﬂow before surgery and at various post-
operative points in time are presented in Fig 1, A. There
appeared tobe acceleratedbloodﬂowrecovery in the ischemic
hindlimbs of themetformin (300mg/kg/d)-treated group
of WT mice compared with that of the group of untreated
mice. There was a signiﬁcant increase in the ischemic
muscle limb ﬂow in WT mice treated with metformin
(300 mg/kg/d) on postoperative day 28 as demonstrated
by quantitative analysis of hindlimb perfusion (Fig 1, B).
Measuring capillary density and arteriole density in
a histologic section harvested from the ischemic muscle
assessed the extent of revascularization at the microcircula-
tory level. Representative photomicrographs of endothelial
cell marker CD31-stained muscle tissue are shown in Fig 2,
A. On postoperative day 28, metformin-treated WT mice
had signiﬁcantly greater capillary density in the ischemic
hindlimb than nontreated WT mice, as demonstrated by
quantitative analysis of CD31-positive cells (Fig 2, B).
Metformin-treated WT mice also demonstrated signiﬁ-
cantly greater arteriole density in the ischemic hindlimb
than nontreated WT mice (Fig 2, C and D). Thus, treat-
ment with metformin promoted revascularization in













































Fig 2. Increased capillary and arteriole density in ischemic metformin-treated wild-type (WT) mice. A, Immuno-
staining of ischemic tissues with anti-CD31 monoclonal antibody (green) on postoperative day 28 (400). B,
Quantitative analysis of capillary density in WT (n ¼ 10 in each group) treated with or without metformin
(300 mg/kg/d). C, Immunostaining of ischemic tissues with anti-a-smooth muscle actin antibody (red) on post-
operative day 28 (400). D, Quantitative analysis of arteriole density in WT (n ¼ 10 in each group) treated with or
without metformin (300 mg/kg/d).
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tion in ischemic muscle. eNOS plays an important
role in regulating revascularization in response to tissue
ischemia.26 Western blot analysis was employed to assess
the expression and phosphorylation of eNOS in ischemic
adductor muscle at day 7 after surgery to explore the
role of eNOS in metformin-mediated improvement of
ischemia-induced revascularization. Although there was
no difference between the two experimental groups of WT
mice in relation to the total eNOS protein expression
in ischemic muscles, there was signiﬁcantly greaterphosphorylation of eNOS in the ischemic muscle in the
metformin-treated WT mice (Fig 3, A and B).
The direct affect of AMPK on phosphorylate eNOS
has been previously reported.21 Thus, we assessed the
expression and phosphorylation of AMPK in ischemic
adductor muscle using Western blot analysis to clarify
the role of AMPK in revascularization induced by met-
formin treatment. The results indicate that there was
signiﬁcant stimulation of phosphorylation of AMPK

















































































Fig 3. Effect of metformin on phosphorylation of adenosine monophosphate-activated protein kinase (AMPK) and
endothelial nitric oxide synthase (eNOS) in ischemic muscle in wild-type (WT) mice. Western immunoblots with the
indicated antibodies were performed on the ischemic adductor muscle of WT mice treated with or without metformin
(300 mg/kg/d) at 7 days after surgery. A, The representative immunoblots and B, quantitative analysis of relative
changes in total and phosphorylated AMPK and eNOS. AMPK and eNOS were normalized to a-tubulin signal and
expressed as percentage of the signal intensity of untreated WT mice (n ¼ 10).
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revascularization. For additional analysis of the involve-
ment of eNOS signaling in revascularization by metformin,
we explored metformin’s impact on blood ﬂow in ischemic
muscles of eNOS-KO mice. Upon LDBF analysis, no
signiﬁcant differences in limb perfusion were seen between
metformin-treated and nontreated eNOS-KO mice on
postoperative day 0, 3, 7, and 14 (Fig 4, A). Because
eNOS-KO mice exhibit severe ischemia-induced vascular
insufﬁciency, which is accompanied by amputation, we
assessed lower limb function and tissue salvage postsurgery
using a clinical scoring system.32 Similarly, there was no
signiﬁcant difference between the index of severity of tissue
ischemia after hindlimb surgery between metformin-
treated and nontreated eNOS-KO mice (Fig 4, B). In
addition, according to immunohistochemical analysis,
there was no signiﬁcant difference in capillary and arteriole
density between metformin-treated and nontreated eNOS-
KO mice on postoperative day 28 (Fig 4, C andD). Finally,
we conﬁrmed that there was an increase in the phosphor-
ylation of AMPK in ischemic muscle of metformin-treated
eNOS-KO mice in comparison to nontreated eNOS-KO
mice (Fig 4, E).
DISCUSSION
We demonstrated that treatment with metformin
promoted revascularization in response to ischemia, as
seen in a state of vascular insufﬁciency created using
a mouse model in the present study. Metformin treatment
in WT mice stimulated recovery of limb perfusion and
enhanced capillary density that was greater than seen in
untreated mice, which was accompanied by eNOSactivation. The beneﬁcial actions of metformin on revascu-
larization were nulliﬁed in eNOS-KO mice. Therefore,
metformin has a beneﬁcial effect on revascularization under
ischemic conditions through eNOS signaling.
Type 2 diabetes increases the morbidity of coronary
and peripheral artery diseases because of the occurrence
of microvascular rarefaction and impaired collateral vessel
growth, which are typical of ischemic conditions.33,34
There is greater vulnerability to ischemic injury as well
impairment of wound healing in the presence of these
circulatory changes, ultimately yielding a more frequent
occurrence of lower-limb amputation. In the present
study, daily oral administration of metformin fostered
revascularization in the presence of tissue ischemia.
Thus, in addition to its glucose lowering effect, metfor-
min could be beneﬁcial for diabetes-related vascular
complications.
A number of articles reported metformin improves
tube formation via AMPK activation and increases eNOS
activity in endothelial cells in vitro.16,29,35 Previously, we
have reported that AMPK activation in ischemic muscle
enhances angiogenic repairs of ischemic muscle in
vivo.23,27,36 Metformin also improved cardiac function,
an effect that was facilitated by the activation of AMPK
and eNOS in a mouse model of myocardial infarction
in vivo.17 In the present study, despite the increased
AMPK phosphorylation levels in ischemic muscle in
eNOS-KO mice following metformin treatment, metfor-
min did not affect perfusion recovery of ischemic limbs in
eNOS-KO mice. Collectively, the ability of metformin to
foster angiogenesis is likely a result of the stimulation of


















































































































Fig 4. Adenosine monophosphate-activated protein kinase (AMPK)/endothelial nitric oxide synthase (eNOS)
pathway is required for metformin-induced revascularization. A, Quantitative analysis of ischemic/normal laser
Doppler blood ﬂowmetry (LDBF) ratio in eNOS deﬁcient (eNOS-KO) mice (n ¼ 5 in each group) treated with or
without metformin (300 mg/kg/d). B, Clinical score in eNOS-KO mice treated with or without metformin (300 mg/
kg/d) as determined by an index of severity of limb ischemia. C, Quantitative analysis of capillary density in eNOS-KO
mice (n ¼ 5 in each group) treated with or without metformin (300 mg/kg/d). D, Quantitative analysis of arteriole
density in eNOS-KO mice (n ¼ 5 in each group) treated with or without metformin (300 mg/kg/d). E, The
representative immunoblots and quantitative analysis of relative changes in phosphorylated AMPK in eNOS-KO mice
treated with or without metformin at 7 days after surgery. Western immunoblots with the indicated antibodies were
performed on the ischemic adductor muscle of eNOS-KO mice treated with or without metformin at 7 days after
surgery. Phosphorylation of AMPK was normalized to a-tubulin signal and expressed as a percentage of the signal
intensity of untreated eNOS-KO mice (n ¼ 5).
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of metformin in regulating angiogenesis has produced con-
ﬂicting results. In agreement with our data, metformin
treatment produces an increase in angiogenesis in endothe-
lial cells.16,35 In contrast, others report that metformin
inhibits the growth of tumors in vivo by inhibition of neo-
vascularization.37,38 This discrepancy is possibly due to
differences in the assay systems utilized for angiogenesis.
There is also the possibility that metformin regulates path-
ologic and physiological angiogenesis differentially as has
been put forth to explain the effects of statins on vascular-
ization.39 Notably, it is recognized that activation of
AMPK/eNOS signaling confers a proangiogenic pheno-
type in ischemic hindlimb.23,26,27 Taking all these observa-
tions together suggests that the induction of AMPK/
eNOS signaling by metformin treatment is able to facilitate
revascularization in the presence of muscle ischemia.
The present study has several limitations. First, we used
a dosage of 300 mg/kg/ to activate AMPK/eNOS in
mice. This dosage is higher than the usual dosage used in
the case of humans. Nevertheless, therapeutic methods tar-
geting the activation AMPK/eNOS could prove to be
beneﬁcial in the treatment of cardiovascular disease in
humans. Second, the entire left femoral artery and vein
were surgically removed in our mouse model of revascular-
ization. This model may not replicate the human situation
of arterial atherosclerotic occlusion. Therefore, it is neces-
sary to carry out supplementary experimental research to
obtain assessments using various models (chronic limb
ischemia model, diabetic model, and large animal model).
In patients suffering from peripheral arterial disease,
the incidence of the diabetes mellitus is high.40 Diabetes
is one of the comorbidities affecting wound healing. In
Japan, in particular, the complication rates of diabetes mel-
litus and end-stage renal disease are high in patients with
critical limb ischemia. In addition to the glucose-lowering
effect of metformin, the beneﬁcial effects of metformin
on cardiovascular disease have been demonstrated in
various clinical studies.1-3,5 In the present study, metformin
activated the AMPK-eNOS signaling pathway and, thus,
promoted angiogenic repair in ischemic limbs. These
results offer important fundamental data clarifying the efﬁ-
cacy of the clinical trials.
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